Accuray CE Marks Its New Radixact(TM) System

Sunnyvale, California (ots/PRNewswire) -

Next Generation Image-Guided Radiation Therapy Platform and
Integrated Software Solutions are Now Available for Use by Clinicians
in the European Union

Accuray Incorporated (NASDAQ: ARAY) announced today that it has CE
marked its Radixact(TM) Treatment Delivery System, Accuray
Precision(TM) Treatment Planning System and iDMS(TM) Data Management
System. The next generation hardware and software solutions,
together, make up the new Radixact platform, which represents a major
step forward in the evolution of Accuray's existing TomoTherapy®
System in treatment speed and ease of use. The platform will now be
available in certain markets in the European Union (EU), in addition
to the U.S. market where it received FDA 510(k) clearance in June
2016.

(Logo: http://photos.prnewswire.com/prnh/20151126/291246LOGO )

(Photo: http://photos.prnewswire.com/prnh/20160809/396644 )

The Radixact System is a "smart" system that will enable faster,
more efficient delivery of extremely precise treatment to a wider
range of cancer patients across the European market. It features a
more powerful linear accelerator, MVCT imaging and helical treatment
delivery, so clinicians can apply highly conformal and homogeneous
dose distributions to any target volume, while precisely sparing
normal healthy tissue during each treatment fraction.

"Radixact System availability in the EU is a critical component of
our commercial launch strategy for this innovative platform," said
Joshua H. Levine, president and chief executive officer of Accuray.
"We have shipped the first commercially released Radixact System to a
site in the U.S. and expect our first EU shipment during our Fiscal
Q1 2017. The system is a key driver of our short- and long-term
growth outlook, as well as our ability to achieve sustainable
profitability, and we are excited about the reception the system is
receiving in the marketplace."

The Radixact platform is comprised of three entirely new,
transformative technologies:

- Radixact Treatment Delivery System: Taking the industry-leading
capabilities of the TomoTherapy Systems to a new level.
- Accuray Precision Treatment Planning System: Smart, automated
workflows and mid-course decision-making tools that enable
clinicians to adapt delivery according to changes in tumor size,
shape and location.
- iDMS Data Management System: Seamless management of patient data
across multiple Radixact Systems and clinics, from a single point
of control.

For Important Safety information about radiotherapy please refer
to: http://www.accuray.com/safety-statement-radiation-treatment.

For more information about the Radixact platform, visit:
http://www.accuray.com/radixact.

About Accuray

Accuray Incorporated (NASDAQ: ARAY) is a radiation oncology
company that develops, manufactures and sells precise, innovative
tumor treatment solutions that set the standard of care with the aim
of helping patients live longer, better lives. The company's
leading-edge technologies deliver the full range of radiation therapy
and radiosurgery treatments. For more information, please visit
http://www.accuray.com .

Safe Harbor Statement

Statements made in this press release that are not statements of
historical fact are forward-looking statements and are subject to the
"safe harbor" provisions of the Private Securities Litigation Reform
Act of 1995. Forward-looking statements in this press release relate,
but are not limited, to clinical applications, regulatory approvals
and launches of new products, market uptake of recently launched
products, and Accuray's leadership position in radiation oncology
innovation and technologies. Forward-looking statements are subject
to risks and uncertainties that could cause actual results to differ
materially from expectations, including but not limited to the risks
detailed from time to time under the heading "Risk Factors" in the
company's report on Form 10-K, filed on August 28, 2015, the
company's reports on Form 10-Q, filed on November 5, 2015, February
1, 2016 and April 29, 2016, and the company's other filings with the
SEC.

Forward-looking statements speak only as of the date the
statements are made and are based on information available to Accuray
at the time those statements are made and/or management's good faith
belief as of that time with respect to future events. The company
assumes no obligation to update forward-looking statements to reflect
actual performance or results, changes in assumptions or changes in
other factors affecting forward-looking information, except to the
extent required by applicable securities laws. Accordingly, investors
should not put undue reliance on any forward-looking statements.

ots Originaltext: Accuray
Im Internet recherchierbar: http://www.presseportal.de

Contact:
Sancie Nakarat
Accuray
+33 (0)6-81-36-84-34
snakarat@accuray.com

Investor Contact: Doug Sherk
Investor Relations
EVC Group
+1 (415) 652-9100
dsherk@evcgroup.com